Purpose <p>Children with unresectable cervicomedullary tumors (CMTs) demonstrate poor progression-free survival when treated with conventional chemotherapy and radiotherapy. The <i>BRAFV600E</i> mutation, commonly identified in low-grade gliomas, represents a therapeutic target for mutation-specific kinase inhibitors. This study aims to emphasize the potential role of BRAF inhibitors as upfront targeted therapy in selected tumors where surgical resection is not feasible.</p> Methods <p>A retrospective analysis was conducted on four pediatric patients with unresectable cervicomedullary low-grade gliomas harboring the <i>BRAFV600E</i> mutation. All patients were treated with the BRAF inhibitor dabrafenib, either as first-line or second-line therapy.</p> Results <p>Dabrafenib was administered as first-line therapy in two patients and as second-line therapy in two others. All patients experienced rapid tumor regression with significant and durable clinical and radiologic responses. Three patients tolerated long-term therapy (up to 9&#xa0;years) without significant toxicity. One patient discontinued treatment after 1&#xa0;year due to a serious adverse event, which resolved upon withdrawal of therapy.</p> Conclusion <p>Dabrafenib demonstrated clinical and radiographic efficacy and was generally well tolerated in pediatric patients with unresectable <i>BRAFV600E</i>-mutant CMTs. These findings suggest that upfront BRAF inhibition may serve as a viable therapeutic alternative to conventional chemotherapy, radiotherapy, or attempted resection in selected cases. Further prospective studies are warranted to define the optimal timing, duration, and long-term safety of targeted therapy in this population.</p>